How gut bacteria affect lung problems after blood cell transplants
Microbiota Regulation of Pulmonary Complications Post-HCT
This study is looking at how the bacteria in your lungs might change after a stem cell transplant and how those changes could lead to problems like lung injury or pneumonia, with the goal of finding better ways to help you recover and stay healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10910901 on NIH RePORTER |
What this research studies
This research investigates the role of the microbiome in lung complications that can arise after hematopoietic cell transplantation (HCT). It focuses on understanding how changes in lung bacteria can lead to serious issues like lung injury and pneumonia in patients who have undergone HCT. By studying these changes, the researchers aim to develop new treatment strategies that could improve recovery and reduce the risk of lung-related complications. The approach includes using animal models to mimic human conditions and analyze the effects of microbiota on lung health.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have undergone hematopoietic cell transplantation and are experiencing or at risk for pulmonary complications.
Not a fit: Patients who have not undergone hematopoietic cell transplantation or those without any lung complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments that enhance recovery and reduce lung complications for patients undergoing HCT.
How similar studies have performed: Previous research has shown promising results in understanding the microbiome's impact on various health conditions, suggesting that this approach could yield significant insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Zhou, Xiaofeng — University of Michigan at Ann Arbor
- Study coordinator: Zhou, Xiaofeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.